Von Hippel-Lindau (VHL) disease is a progressive autosomal dominant multisystem disorder that is associated with a germ line mutation of the VHL gene on the short arm of chromosome 3. A variety of benign and malignant diseases, including eye and CNS hemangioblastomas, renal cell carcinoma and pheochromocytoma are the major components. Gastroenteropancreatic neuroendocrine tumors are also listed among the typical complications, although these occur seldom. Virtually all such tumors are pancreatic islet cell tumors. VHL-associated islet cell tumors are mostly hormone-inactive. They can be detected during screening investigations according to the multidisciplinary disorder or by workup of space-occupying lesions. There are no specific predictors for malignancy in VHL-associated islet cell neoplasias, but tumors smaller than 3 cm in diameter are believed to be always benign. Gadolinium-enhanced MRI is currently the imaging method of choice, but contrast-enhanced CT is also a diagnostic option. The spectrum of manifestations is illustrated by selected cases.

1.
Neumann HPH: Basic criteria for clinical diagnosis and genetic counselling in Von Hippel-Lindau syndrome. Vasa 1987;16:120–226.
2.
Neumann HPH: Von Hippel-Lindau Erkrankung – Prävention und Rezidivprophylaxe bei einem hereditären Tumorsyndrom – Ein Modellprojekt. Preisschrift Hufeland-Preis, Selbstverlag, 1998.
3.
Von Hippel E: Über eine sehr seltene Erkrankung der Netzhaut. Albrecht Von Graefes Arch Ophthalmol 1904;59:83–86.
4.
Von Hippel E: Die anatomische Grundlage der von mir beschriebenen ‘sehr seltenen Erkrankung der Netzhaut’. Albrecht Von Graefes Arch Ophthalmol 1911;79:350–377.
5.
Lindau A: Studien über Kleinhirnzysten. Bau Pathogenese und Beziehungen zur Angiomatosis retinae. Acta Pathol Microbiol Scand Suppl 1926;l:1–129.
6.
Schmidt D, Natt E, Neumann HPH: Long-term results of laser treatment for retinal angiomatosis in Von Hippel-Lindau disease. Eur J Med Res 2000;5:47–58.
7.
Neumann HP, Eggert HR, Scheremet R, Schumacher M, Mohadjer M, Wakhloo AK, Volk B, Hettmannsperger U, Riegler P, Schollmeyer P, Wiestler OD: Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 1992;55:898–901.
8.
Neumann HPH, Zbar B: Renal cysts, renal cancer and Von Hippel-Lindau disease. Kidney Int 1997;51:16–26.
9.
Neumann HPH, Bender BU, Berger DP, Laubenberger J, Schultzeseemann W, Wetterauer U, Ferstl FJ, Herbst EW, Schwarzkopf G, Hes FJ, Lips CJM, Lamiell JM, Masek O, Riegler P, Mueller B, Glavac D, Brauch H: Prevalence, morphology and biology of renal cell carcinoma in Von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 1998;160:1248–1254.
10.
Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G: Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329:1531–1538.
11.
Janetschek G, Finkenstedt G, Gasser R, Waibel UG, Peschel R, Bartsch G, Neumann HPH: Laparoscopic surgery for pheochromocytoma: Adrenalectomy, partial resection, excision of paragangliomas. J Urol 1998;160:330–334.
12.
Neumann HPH, Bender BU, Reincke M, Eggstein S, Laubenberger J, Kirste G: Adrenal sparing surgery for pheochromocytoma. Br J Surg 1999;84:94–97.
13.
Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–1466.
14.
Walz MK, Peitgen K, Neumann HP, Janssen OE, Philipp T, Mann K: Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg 2002;26:1005–1012.
15.
Neumann HPH, Reincke M, Bender BU, Elsner R, Janetschek G: Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999;84:2608–2610.
16.
Neumann HPH, Dinkel E, Brambs H, Wimmer B, Friedburg H, Sigmund G, Riegler P, Haag K, Schollmeyer P, Wiestler OD: Pancreatic lesions in the Von Hippel-Lindau syndrome. Gastroenterology 1991;101:465–471.
17.
Deboever G, Dewulf P, Maertens J: Common bile duct obstruction due to pancreatic involvement in the von Hippel-Lindau syndrome. Am J Gastroenterol 1992;87:1866–1868.
18.
Cheng TY, Su CH, Shyr YM, Lui WY: Management of pancreatic lesions in von Hippel-Lindau disease. World J Surg 1997;21:307–312.
19.
Lamiell JM, Salazar FG, Hsia YE: Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989;68:1–29.
20.
Buetow PC, Miller DL, Parrino TV, Buck JL: Islet cell tumours of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization. Radiographics 1997;17:453–472.
21.
Hull MT, Warfel KA, Muller J, Higgins JT: Familial islet cell tumors in Von Hippel-Lindau’s disease. Cancer 1979;44:1523–1526.
22.
Binkovitz LA, Johnson CD, Stephens DH: Islet cell tumors in von Hippel-Lindau disease: Increased prevalence and relationship to the multiple endocrine neoplasias. Am J Radiol 1990;155:501–505.
23.
Hough DM, Stephens DH, Johnson CD, Binkovitz LA: Pancreatic lesions in von Hippel-Lindau disease: Prevalence, clinical significance, and CT findings. Am J Radiol 1994;162:1091–1094.
24.
Fishman RS, Bartholomew LG: Severe pancreatic involvement in three generations in von Hippel-Lindau disease. Mayo Clin Proc 1979;54:329–331.
25.
Cornish D, Pont A, Minor D, Coombs JL, Bennington J: Metastatic islet cell tumor in von Hippel-Lindau disease. Am J Med 1984;77:147–150.
26.
Choyke PL, Filling-Katz MR, Shawker TH, Gorin MB, Travis WD, Chang R, Seizinger BR, Dwyer AJ, Linehan WM: Von Hippel-Lindau disease: Radiologic screening for visceral manifestations. Radiology 1990;174:815–820.
27.
Chambers TP, Fishman EK, Hruban RH: Pancreatic metastases from renal cell carcinoma in von Hippel-Lindau disease. Clin Imaging 1997;21:40–42.
28.
Doherty GM: Multiple endocrine neoplasia type 1: Duodenopancreatic tumors. Surg Oncol 2003;12:135–143.
29.
Alberts MW, McMeekin JO, George JM: Mixed multiple endocrine neoplasia syndromes. JAMA 1980;244:1236–1237.
30.
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O’Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, and Thakker RV: Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 1996;89:653–669.
31.
Carty SE, Helm AK, Amico JA, Clarke MR, Foley TP, Watson CG, Mulvihill JJ: The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998;124:1106–1114.
32.
Sigl E, Behmel A, Henn T, Wirnsberger G, Weinhausl A, Kaserer K, Niederle B, Pfragner R: Cytogenetic and CGH studies of four neuroendocrine tumors and tumor-derived cell lines of a patient with multiple endocrine neoplasia type 1. Int J Oncol 1999;15:41–51.
33.
Dackiw APB, Cote GJ, Fleming JB, Schultz PN, Stanford P, Vassilopoulou-Sellin R, Evans DB, Gagel RF, Lee JE: Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery 1999;126:1097–1104.
34.
Kopp I, Bartsch D, Wild A, Schilling T, Nies C, Bergenfelz A, Reider H, Simon B, Rothmund M: Predictive genetic screening and clinical findings in multiple endocrine neoplasia type 1 families. World J Surg 2001;25:610–616.
35.
Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS: A mouse model of MEN1 develops multiple endocrine tumors. Proc Nat Acad Sci USA 2001;98:1118–1123.
36.
Sugiyama M, Katsura M, Yamamoto K, Nouchi W, Abe N, Hatano N, Atomi Y: Pancreatic metastasis from renal cell carcinoma causing massive gastrointestinal bleeding in von Hippel-Lindau disease. Hepatogastroenterology 1999;46:1199–1201.
37.
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al: Identification of the Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317–1320.
38.
Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan WM: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417–423.
39.
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmertbuck MR, Skarulis MC, Doppman JL, Kim YS, Lubensky IA, Zhuang Z, Green JS, Guru SC, Manickam P, Olufemi SE, Liotta LA, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ: Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169–1175.
40.
Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding C, Harding B, Besser GM, Edwards CR, Monson JP, Sampson J, Wass JA, Wheeler MH, Thakker RV: Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232–244.
41.
Poncin J, Abs R, Velkeniers B, Bonduelle M, Abramowicz M, Legros JJ, Verloes A, Meurisse M, Van Gaal L, Verellen C, Koulischer L, Beckers A: Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Hum Mutat 1999;13:54–60.
42.
Kees A: Malignant carcinoid and phaeochromocytoma in von Hippel-Lindau disease – A case report. Wien Klin Wochenschr 1980;92:218–221.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.